Clinical trials · Colorado
Advanced Cancer clinical trials in Colorado
We’re tracking 120 recruiting advanced cancer studies with a site in Colorado — including Phase 1, Phase 1/Phase 2, Phase 2, Phase 2/Phase 3 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies in Colorado
- NCT06116682RecruitingPhase 2
Targeted treatment for MET-positive advanced lung cancer
This trial tests a targeted therapy for people with advanced non-small cell lung cancer whose tumors have extra copies of the MET gene. It's for those whose cancer has progressed after at least one prior treatment.
Fort Collins, ColoradoAges 18 years+ - NCT06417814RecruitingPhase 3
Study of Dato-DXd with or without osimertinib for EGFR-mutated lung cancer
This trial tests a new drug, Dato-DXd, given alone or with osimertinib, versus standard chemotherapy for people with a specific type of advanced lung cancer (EGFR-mutated non-small cell lung cancer) that has worsened after osimertinib treatment.
Fort Collins, ColoradoAges 18–130 - NCT06561685RecruitingPhase 1
Study of LY4050784 for Advanced Solid Tumors with SMARCA4 Changes
This trial tests a new drug, LY4050784, for people with advanced solid tumors that have a specific change in a gene called SMARCA4 (BRG1). The study aims to see if the drug is safe and effective. It may be an option for those who have tried other treatments or have no standard options left.
Aurora, ColoradoAges 18 years+ - NCT06667076RecruitingPhase 2
Amivantamab combinations for advanced EGFR-mutant lung cancer
This trial tests two treatment combinations for people with a specific type of advanced lung cancer that has an EGFR mutation. One group gets amivantamab plus lazertinib, and the other gets amivantamab plus chemotherapy. The goal is to see which combo works better.
Denver, ColoradoAges 18 years+ - NCT05136196RecruitingPhase 2
Cabozantinib plus nivolumab for advanced melanoma or head-neck cancer
This trial tests whether combining two immunotherapy medicines—cabozantinib and nivolumab—can shrink advanced melanoma or certain head-and-neck squamous cell cancers. It is mainly for people whose cancer has grown after prior PD-1 treatment.
Aurora, ColoradoAges 18 years+ - NCT06926868RecruitingPhase 2/Phase 3
Study of a new drug versus chemotherapy for advanced triple-negative breast cancer
This trial tests a new investigational drug called izalontamab brengitecan against standard chemotherapy for people with advanced triple-negative breast cancer who cannot receive immunotherapy. The goal is to see if the new drug works better at shrinking or slowing the cancer.
Aurora, ColoradoAges 18 years+ - NCT07519655RecruitingPhase 1
New Cancer Drug Treatment for Advanced Lung, Esophageal, or Skin Cancer
This study tests a new drug called PF-08046033 in people with advanced lung cancer (NSCLC), esophageal cancer (ESCC), or melanoma (skin cancer) that has spread or can't be surgically removed. The drug targets a specific protein to help slow or stop cancer growth.
Denver, ColoradoAges 18 years+ - NCT06999187RecruitingPhase 1
Study of DR-0202 for advanced solid tumors after multiple treatments
This trial tests a new drug, DR-0202, for people with certain advanced cancers that have not responded to at least two prior treatments. It may be an option if standard treatments are no longer working.
Denver, ColoradoAges 18 years+ - NCT05327010RecruitingPhase 2
Testing a new drug combination for advanced solid tumors
This trial is studying whether a new combination of two cancer drugs, ZEN003694 and talazoparib, can help people with advanced solid tumors that have not responded to other treatments. Talazoparib is a type of drug that targets cancer cells with certain DNA repair problems. The study is divided into groups based on specific gene mutations or previous treatment responses.
Aurora, ColoradoAges 18 years+ - NCT06765109RecruitingPhase 3
Testing neladalkib for untreated ALK-positive lung cancer
This study tests a new pill called neladalkib to see if it works better than the current standard treatment (alectinib) for people with ALK-positive lung cancer who have not yet received any cancer therapy for advanced disease. It may be a good option if you have ALK-positive NSCLC and have not been treated before.
Boulder, ColoradoAges 18 years+ - NCT05245500RecruitingPhase 1
Study drug for solid tumors with MTAP gene deletion
This Phase 1 trial studies MRTX1719, a new medicine, in solid tumors that have a missing MTAP gene (MTAP deletion). It aims to find the safest dose and check how the drug affects the tumor.
Lone Tree, ColoradoAges 18 years+ - NCT06119581RecruitingPhase 3
Oloromosib with Immunotherapy as First Treatment for KRAS G12C Lung Cancer
This trial tests a new targeted pill (olomorasib) combined with immunotherapy (pembrolizumab) and possibly chemotherapy for people with advanced non-small cell lung cancer that has a KRAS G12C mutation and has not been treated before.
Lone Tree, ColoradoAges 18 years+ - NCT06128551RecruitingPhase 1/Phase 2
Testing two targeted drugs for KRAS G12C advanced cancer
This study tests two oral medicines (elironrasib and daraxonrasib) given alone or together to see if they can shrink tumors or slow down cancer growth in people with advanced solid tumors that have a KRAS G12C mutation. It is for people who have already tried other treatments.
Aurora, ColoradoAges 18 years+ - NCT06793215RecruitingPhase 3
Divarasib plus pembrolizumab for KRAS G12C lung cancer
This trial compares a new targeted drug (divarasib) combined with an immunotherapy (pembrolizumab) versus standard chemotherapy plus immunotherapy for people with advanced lung cancer that has a specific KRAS G12C mutation. It aims to see if the new combination works better and is safe.
Colorado Springs, ColoradoAges 18 years+ - NCT06655246RecruitingPhase 1
Ziftomenib and imatinib for advanced GIST
This trial tests a new drug, ziftomenib, combined with imatinib for people with advanced or spreading gastrointestinal stromal tumors (GIST) that have a KIT mutation. It may help if your GIST has gotten worse while on imatinib.
Aurora, ColoradoAges 18 years+ - NCT06026410RecruitingPhase 1
KO-2806 for advanced solid tumors
This trial tests a new drug called KO-2806, alone or with other treatments, for people with advanced solid tumors that have specific gene changes (like HRAS or KRAS mutations). It may help if standard treatments have stopped working.
Denver, ColoradoAges 18 years+ - NCT07431281RecruitingPhase 3
New drug combo for advanced stomach cancer with CLDN18.2
This trial tests a new drug combination for people with advanced stomach cancer that has not been treated before. It looks at two groups: one with PD-L1 (a protein that helps decide if immunotherapy works), and one without. The treatment includes an antibody-drug conjugate (Sonesitatug Vedotin) plus standard chemotherapy, with or without an immunotherapy drug.
Denver, ColoradoAges 18 years+ - NCT07182149RecruitingPhase 1
Testing a new drug for advanced solid tumors
This trial tests a new drug called NRM-823 for people with several types of advanced cancer that have stopped responding to standard treatments. The goal is to see if the drug is safe and how well it works.
Denver, ColoradoAges 18 years+ - NCT05677490RecruitingPhase 3
Chemo options, with or without nivolumab, for HER2-negative stomach cancer
This Phase 3 trial compares two standard chemotherapy regimens for advanced stomach, esophagus, or gastroesophageal junction cancer that is HER2-negative. It also tests whether adding nivolumab (an immune therapy) improves outcomes.
Aurora, ColoradoAges 18 years+ - NCT06720987RecruitingPhase 1
KQB365 for advanced solid tumors with KRAS mutations
This trial tests a new drug called KQB365, alone or with other drugs, for people with advanced solid tumors that have a specific KRAS mutation (G12C or G12S). It aims to see if the treatment is safe and effective.
Denver, ColoradoAges 18 years+ - NCT07005102RecruitingPhase 2/Phase 3
Telisotuzumab adizutecan and osimertinib for EGFR-positive lung cancer
This trial tests a new drug combination (telisotuzumab adizutecan plus osimertinib) as a first treatment for adults with a specific type of advanced lung cancer that has an EGFR mutation. The goal is to see if the combination is safe and works better than standard care.
Aurora, ColoradoAges 18 years+ - NCT06627647RecruitingPhase 3
Comparing two immunotherapy drugs for advanced lung cancer
This trial tests a new immunotherapy drug, rilvegostomig, against the standard pembrolizumab, both given with chemotherapy, as a first treatment for advanced non-squamous non-small cell lung cancer (NSCLC) that cannot be cured with surgery or radiation. It is for people whose tumors have high PD-L1 levels and do not have certain genetic mutations.
Lone Tree, ColoradoAges 18 years+ - NCT07291037RecruitingPhase 3
Study of datopotamab deruxtecan vs docetaxel for advanced lung cancer
This trial tests a new drug, datopotamab deruxtecan, against a standard chemotherapy (docetaxel) for people with advanced non-squamous lung cancer that has gotten worse after previous treatment. It is for those who do not have certain genetic changes (like EGFR, ALK, or ROS1) and whose tumors have a protein called TROP2.
Grand Junction, ColoradoAges 18 years+ - NCT05482893RecruitingPhase 1/Phase 2
Spevatamig for advanced stomach, pancreas, or bile duct cancer
This trial tests a new drug called Spevatamig (PT886), alone or with different chemotherapy and/or immunotherapy combinations, for people with certain advanced stomach, pancreatic, or bile duct cancers. The goal is to see if it shrinks tumors and is safe.
Denver, ColoradoAges 18 years+
Advanced Cancer trials by city in Colorado
Where these studies are running in Colorado
Institutions with a site for the recruiting advanced cancer studies listed above.
- Sarah Cannon Research Institute · 6 studies
- Rocky Mountain Cancer Centers · 5 studies
- Research Site · 4 studies
- Advanced Neurology of Colorado · 3 studies
- Poudre Valley Hospital · 3 studies
- Presbyterian/St. Luke's Medical Center · 3 studies
- UCHealth Greeley Hospital · 3 studies
- UCHealth Medical Center of the Rockies · 3 studies
What taking part in a advanced cancer study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Advanced Cancer trials in other states
Common questions
- Are there advanced cancer clinical trials in Colorado?
- Yes. We're currently tracking 120 recruiting advanced cancer studies with a site in Colorado, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a advanced cancer study in Colorado?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Colorado to take part?
- Not necessarily. These studies have a site in Colorado, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a advanced cancer trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New advanced cancer studies open in Colorado regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.